BMJ Pre-Submission Checklist: Clinical Practice Readiness

4. Is the study design appropriate for the clinical claims?

BMJ favors randomized trials, large cohort studies, systematic reviews, and health services research. Observational studies are published but face higher scrutiny. The key question: is the design strong enough that a clinician would change their practice based on these results?

5. Are the statistical methods rigorous enough for independent review?

BMJ sends papers to independent statistical reviewers. Like NEJM and JAMA, the statistical review evaluates sample size justification, analytical methods, missing data handling, and multiplicity corrections. Prepare for questions your clinical reviewers would not ask.

6. Does the paper have international applicability?

This is where BMJ differs most from NEJM and JAMA. BMJ has a genuinely international editorial perspective. Research relevant to healthcare systems in multiple countries, studies from low- and middle-income settings, and work addressing global health challenges receive priority consideration. If your study is US-only, you need to explain why the findings apply internationally.

7. Is the paper framed for an international clinical audience?

Drug names, clinical pathways, and healthcare system references that are specific to one country should be contextualized. US brand names should include generic names. UK-specific NHS terminology should be explained for international readers.

8. Is the reporting checklist complete?

CONSORT for trials (2025 update if applicable), STROBE for observational, PRISMA for systematic reviews. BMJ published the CONSORT 2025 statement alongside NEJM, Lancet, and Nature Medicine. Complete the checklist with specific page references.

9. Are ethics approvals, trial registration, and data sharing documented?

Trial registration is required before enrollment. Ethics approval must be stated with institution and approval number. BMJ requires a data sharing statement. The journal offers a subscription track with no APC (articles free after 6 months, immediate free access in low-income countries), which satisfies many funder open access mandates.

10. Does the cover letter explain clinical impact concisely?

BMJ editors may reject within the first hour of submission if they are convinced the journal is not the right fit. The cover letter is the first thing they read. Keep it short: state the finding, the clinical implication, and why BMJ specifically is the right journal. Do not spend a paragraph on background.

If the paper addresses an ongoing public health emergency or has immediate policy implications, flag this explicitly in the cover letter. BMJ has a fast-track process for time-sensitive public health research.

BMJ uses open peer review, meaning reviewer names are published alongside the accepted paper. This creates a different review dynamic than journals with anonymous review: reviewers tend to be more constructive and less arbitrarily harsh, but they also expect higher methodological rigor because their reputation is attached. BMJ also requires data sharing statements and encourages or requires raw data deposit. These transparency requirements should be addressed before submission, not retrofitted during revision.

Check your BMJ readiness automatically. The Manusights free scan evaluates your manuscript against BMJ's editorial standards in about 1-2 minutes.

For a paper targeting BMJ, the BMJ submission readiness check provides verified citations, figure-level feedback, and journal-specific calibration. For career-defining submissions, Manusights Expert Review connects you with reviewers who have published in and reviewed for BMJ.

• the clinical finding does not change practice for general physicians
• the study is too specialty-specific for a general medical journal
• the international relevance is still unclear (especially for single-country studies)
• the study design has limitations that undermine the clinical claims
• the abstract does not state the practice implication in the first 3 sentences
• the paper exceeds the word limit or does not match the required format
• the trial is not registered or registration was retrospective

For more detail, see BMJ Under Review: Status Meanings and the BMJ Submission Guide.

The BMJ problem is usually not basic compliance. It is framing for a general clinical audience without losing methodological precision. We often see strong health-services or specialty studies that are rigorous enough for BMJ but still written as if the reader already works in that niche. The papers that travel best at BMJ make the practice implication obvious early and explain why the result matters beyond one healthcare system.

That usually means adding one more sentence than authors expect: not more background, but a direct explanation of why a clinician in another country should care about the result now.